Release Kinetics of RhBMP-2 Using E-PRF As an Autologous Carrier: an in Vitro Analysis
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Dec 10, 2020
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special growth factor called rhBMP-2, which helps with bone healing, and how it can be delivered using a product made from a patient's own blood called enhanced Platelet-rich fibrin (E-PRF). The researchers want to see how well rhBMP-2 sticks to E-PRF and how quickly it is released over time in a lab setting. They will also compare this method to a currently approved carrier, an absorbable collagen sponge (ACS), and look at combinations of both E-PRF and ACS.
To be eligible for this study, participants need to be at least 18 years old, able to speak and understand English, and a patient at the UAB Dental School. They should also be scheduled for a dental procedure that requires a blood draw, which is part of the usual care. Importantly, the study is not yet recruiting participants, and those who smoke heavily or have certain health issues that could affect healing may not be eligible. Participants will be required to read and understand a consent document explaining the study. Overall, this research aims to improve the ways we help patients heal from bone loss during dental procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- • At least 18 years old
- • Must be a patient of the UAB Dental School
- • Able to read and understand informed consent document
- • Previously treatment planned for a periodontal procedure that will utilize PRF, i.e. requiring venipuncture, as a part of the routine clinical care.
- Exclusion Criteria:
- • Non-English speaking
- • Less than 18 years old
- • Smokers/tobacco users (\>10 cigarettes/day)
- • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing as assessed by Board Certified Periodontal faculty at UAB Department of Periodontology
- • Patient-reported serious adverse events reported with venipuncture, blood sample collection, and/or blood donation.
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Patients applied
Trial Officials
Maria Geisinger, DDS, MS
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials